Alzheimer’s Society responds to EU’s rejection of lecanemab
Alzheimer’s Society responds to EU’s rejection of lecanemab .Today (26 July), the European Union’s drugs regulator, the Committee for Medicinal Products for Human Use (CHMP), has advised that the drug lecanemab, a treatment for Alzheimer’s disease, should not be approved for use in the EU.